| US 7,521,439 B2 | ||
| Glucocorticoid receptor ligands for the treatment of metabolic disorders | ||
| Richard D. Bishop, Grayslake, Ill. (US); Russell Drew Cink, Grayslake, Ill. (US); Bradley D. Gates, Mount Prospect, Ill. (US); Lars T. Hagberg, Stockholm (Sweden); Peer B. Jacobsen, Libertyville, Ill. (US); Philip R. Kym, Grayslake, Ill. (US); Chunqiu Lai, Libertyville, Ill. (US); Marvin Robert Leanna, Grayslake, Ill. (US); James T. Link, Evanston, Ill. (US); Steven J. Richards, Chicago, Ill. (US); Noah Tu, Singapore (Singapore); and Tom W. von Geldern, Richmond, Ill. (US) | ||
| Assigned to Karo Bio AB, Huddinge (Sweden) | ||
| Filed on Jul. 21, 2006, as Appl. No. 11/491,337. | ||
| Application 11/491337 is a continuation of application No. 10/460491, filed on Jun. 12, 2003, granted, now 7,141,559. | ||
| Claims priority of provisional application 60/390056, filed on Jun. 19, 2002. | ||
| Prior Publication US 2007/0027117 A1, Feb. 01, 2007 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/56 (2006.01) | ||
| U.S. Cl. 514—179 [514/866; 514/909] | 12 Claims |
1. A method of selectively antagonizing the effects of the glucocorticoid receptors in a mammal comprising administering a
therapeutically effective amount of a compound of formula (I):
 A is a member selected from the group consisting of —O— or NRA wherein RA is a member selected from the group consisting of hydrogen and alkyl;
R1, R2, R3, R4, R5, R6 and R7 are independently members selected from the group consisting of hydrogen, (C1-C6)-alkyl, alkenyl, alkynyl, alkoxy, hydroxy, alkoxyalkyl, hydroxyalkyl, and halogen; and
R8, R9 and R10 are independently members selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxy, cyano,
halogen, and —NRBRC wherein RB and RC are independently members selected from the group consisting of hydrogen and alkyl.
|